Epigenetic Drugs for Multiple Sclerosis

There is increasing evidence that abnormalities in epigenetic mechanisms of gene expression contribute to the development of multiple sclerosis (MS). Advances in epigenetics have given rise to a new class of drugs, epigenetic drugs. Although many classes of epigenetic drugs are being investigated, at present most attention is being paid to two classes of epigenetic drugs: drugs that inhibit DNA methyltransferase (DNMTi) and drugs that inhibit histone deacetylase (HDACi). This paper discusses the potential use of epigenetic drugs in the treatment of MS, focusing on DNMTi and HDACi. Preclinical drug trials of DNMTi and HDACi for the treatment of MS are showing promising results. Epigenetic drugs could improve the clinical management of patients with MS.

• Publication year

  2016

• Venue

  Current Neuropharmacology

• Publication date

  2016-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/1570159X13666150211001600PMID 26813117PMCID 4787283
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [MR imaging of multiple sclerosis].

  2015cited by this paper
• The epidemiology of multiple sclerosis: insights to disease pathogenesis.

  2014cited by this paper
• Epigenetic drugs in cognitive disorders.

  2014cited by this paper
• Epigenetics of Multiple Sclerosis: An Updated Review

  2014cited by this paper
• TET2 gene expression and 5-hydroxymethylcytosine level in multiple sclerosis peripheral blood cells.

  2014influential reference
• The potential role of epigenetic modifications in the heritability of multiple sclerosis

  2014cited by this paper
• SIRT1 is decreased during relapses in patients with multiple sclerosis.

  2014cited by this paper
• Hypomethylating Agent 5‐Aza‐2′‐deoxycytidine (DAC) Ameliorates Multiple Sclerosis in Mouse Models

  2014cited by this paper
• Methylation differences at the HLA-DRB1 locus in CD4+ T-Cells are associated with multiple sclerosis

  2014cited by this paper
• Epigenetic changes in patients with multiple sclerosis

  2013cited by this paper
• The Epigenome in Personalized Medicine

  2013cited by this paper
• Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis.

  2013influential reference
• Epigenome-wide differences in pathology-free regions of multiple sclerosis–affected brains

  2013cited by this paper
• Epigenetic mechanisms in multiple sclerosis: implications for pathogenesis and treatment.

  2013cited by this paper
• Pathology of Multiple Sclerosis: Where Do We Stand?

  2013cited by this paper
• Dimethyl fumarate regulates histone deacetylase expression in astrocytes.

  2013influential reference
• Multiple sclerosis review.

  2012cited by this paper
• Pathology of demyelinating diseases.

  2012cited by this paper
• Methylation-dependent PAD2 upregulation in multiple sclerosis peripheral blood

  2012influential reference
• Increased promoter methylation of the immune regulatory gene SHP-1 in leukocytes of multiple sclerosis subjects.

  2012cited by this paper
• Animal models of multiple sclerosis: the good, the bad and the bottom line

  2012cited by this paper
• Multiple sclerosis: new insights in pathogenesis and novel therapeutics.

  2012influential reference
• Regulation of Opioid and Cannabinoid Receptor Genes in Human Neuroblastoma and T Cells by the Epigenetic Modifiers Trichostatin A and 5-Aza-2’-Deoxycytidine

  2012cited by this paper
• Impaired neurosteroid synthesis in multiple sclerosis.

  2011cited by this paper
• Gene-environment interactions in human disease: nuisance or opportunity?

  2011cited by this paper
• Changed Histone Acetylation Patterns in Normal-Appearing White Matter and Early Multiple Sclerosis Lesions

  2011influential reference
• MR imaging of multiple sclerosis.

  2011cited by this paper
• Epidemiology of multiple sclerosis.

  2011cited by this paper
• Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

  2011cited by this paper
• Epigenetic management of major psychosis

  2011cited by this paper
• The Therapeutic Potential of HDAC Inhibitors in the Treatment of Multiple Sclerosis

  2011cited by this paper
• Epigenetics and autoimmunity, with special emphasis on methylation.

  2011cited by this paper
• Epigenetic mechanisms in multiple sclerosis and the major histocompatibility complex (MHC).

  2011cited by this paper
• Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis

  2010cited by this paper
• Cortical lesions in multiple sclerosis

  2010cited by this paper
• MicroRNAs miR-17 and miR-20a Inhibit T Cell Activation Genes and Are Under-Expressed in MS Whole Blood

  2010cited by this paper
• Psychotic features associated with multiple sclerosis

  2010cited by this paper
• Parent-of-origin effects at the major histocompatibility complex in multiple sclerosis.

  2010cited by this paper
• The changing demographic pattern of multiple sclerosis epidemiology.

  2010cited by this paper
• Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases.

  2010cited by this paper
• MRI criteria for MS in patients with clinically isolated syndromes

  2010cited by this paper
• Switching on epigenetic therapy.

  2009cited by this paper
• MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47.

  2009cited by this paper
• Pharmacoepigenetics and pharmacoepigenomics.

  2008cited by this paper
• Methylation of class II transactivator gene promoter IV is not associated with susceptibility to Multiple Sclerosis

  2008influential reference
• Multiple sclerosis: could it be an epigenetic disease?

  2008cited by this paper
• Evaluating epigenetic landmarks in the brain of multiple sclerosis patients: a contribution to the current debate on disease pathogenesis.

  2008cited by this paper
• Grey matter pathology in multiple sclerosis.

  2008cited by this paper
• Multiple sclerosis

  2008cited by this paper
• Gray matter involvement in multiple sclerosis

  2007cited by this paper
• Multiple Sclerosis

  2007cited by this paper
• Genes underlying common complex diseases.

  2006cited by this paper
• Diagnosis and treatment of multiple sclerosis

  2006cited by this paper
• Increased Citrullination of Histone H3 in Multiple Sclerosis Brain and Animal Models of Demyelination: A Role for Tumor Necrosis Factor-Induced Peptidylarginine Deiminase 4 Translocation

  2006cited by this paper
• Epigenetic therapy--a new development in pharmacology.

  2006cited by this paper
• Rationale for the Use of Histone Deacetylase Inhibitors as a Dual Therapeutic Modality in Multiple Sclerosis

  2006cited by this paper
• Multiple sclerosis--the plaque and its pathogenesis.

  2006influential reference
• Grey Matter Pathology in Multiple Sclerosis

  2005cited by this paper
• Epialleles and common disease.

  2005cited by this paper
• Depression in multiple sclerosis: a review

  2005cited by this paper
• Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.

  2005influential reference
• Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease.

  2004cited by this paper
• Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions

  2001cited by this paper
• Human morbid genetics revisited: relevance of epigenetics.

  2001cited by this paper
• Corticosteroids or ACTH for acute exacerbations in multiple sclerosis.

  2000cited by this paper
• Cortical lesions in multiple sclerosis.

  1999cited by this paper
• Epidemiology of Multiple Sclerosis in US Veterans

  1997cited by this paper
• Epidemiology of multiple sclerosis.

  1996cited by this paper
• Megadose corticosteroids in multiple sclerosis

  1994cited by this paper
• Multiple sclerosis and other demyelinating diseases.

  1973cited by this paper
• Pathology of the demyelinating diseases.

  1956cited by this paper
• [Multiple sclerosis; review].

  1954influential reference
• Diagnosis and treatment of multiple sclerosis.

  1949cited by this paper

• Immunopathogenesis of multiple sclerosis: molecular and cellular mechanisms and new immunotherapeutic approaches

  2024cites this paper
• The next frontier in multiple sclerosis therapies: Current advances and evolving targets.

  2024cites this paper
• Unraveling the Epigenetic Landscape: Insights into Parkinson’s Disease, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis

  2024cites this paper
• The effect of atomoxetine on cognitive function in patients with multiple sclerosis

  2023cites this paper
• An Updated Review of Epigenetic-Related Mechanisms and Their Contribution to Multiple Sclerosis Disease.

  2022cites this paper
• Nosustrophine: An Epinutraceutical Bioproduct with Effects on DNA Methylation, Histone Acetylation and Sirtuin Expression in Alzheimer’s Disease

  2022cites this paper
• Treatment with non-specific HDAC inhibitors administered after disease onset does not delay evolution in a mouse model of progressive multiple sclerosis.

  2021cites this paper
• Integrated Chemoinformatics Approaches Toward Epigenetic Drug Discovery

  2019cites this paper
• Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human Diseases

  2019cites this paper
• The Beneficial and Debilitating Effects of Environmental and Microbial Toxins, Drugs, Organic Solvents and Heavy Metals on the Onset and Progression of Multiple Sclerosis

  2019cites this paper
• Current advances in multiple sclerosis immunopathology

  2019cites this paper
• Trained Innate Immunity Not Always Amicable

  2019cites this paper
• Pharmacoepigenetics: Basic Principles for Personalized Medicine

  2019cites this paper
• Multiple Sclerosis Diagnosis and Management: A simple Literature Review

  2019cites this paper
• [Actualidades en la inmunopatología de la esclerosis múltiple].

  2018cites this paper
• Cancer Epigenetics for Precision Medicine

  2018cites this paper
• Manipulating macrophage polarization and function using classical HDAC inhibitors: Implications for autoimmunity and inflammation.

  2018cites this paper
• Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis

  2018cites this paper
• Effects of Dietary Nutrients on Epigenetic Changes in Cancer.

  2018cites this paper
• The role of epigenomics in personalized medicine

  2017cites this paper
• Systematic Review of Epigenetic Effects of Pharmacological Agents for Bipolar Disorders

  2017cites this paper
• The Search for Potent, Small‐Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat

  2017cites this paper